The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia
Stephen E. Spurgeon(Oregon Health & Science University), Marc Loriaux(Oregon Health & Science University)
Cited by 53
Related Papers
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib
|Cancer|2018|86
Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia
|Blood Advances|2022|12
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
|Blood Cancer Journal|2025|12